These findings suggest that GnRH-a treatment contributes to an increase in BMI, particularly in CPP children with a normal weight at baseline, although the overall impact on the progression of obesity remains minimal. Here, GNRH1 is linked to obesity due to melanocortin 4 receptor deficiency.